University of Texas MD Anderson Cancer Center

“By 2025, clinical trials will undergo transformative advancements, driven by innovation, patient-centricity, and regulatory evolution.” So said Scott Schliebner , vice president and global head, dru

It has been less than three years since Atlas Venture closed its thirteenth venture capital fund and one thing is unchanged with its fourteenth – the size of the fund. Atlas announced on 5 December th

Generative artificial intelligence firm Generate Biomedicines unveiled a novel protein discovery and development collaboration with Novartis AG on 24 September that it called part of an effort to

AstraZeneca PLC and Daiichi Sankyo Co., Ltd. presented data on 8 and 9 September that seem to support their decision to seek US Food and Drug Administration approval for their TROP2-targeting antib